AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Dipeptidyl peptidase 8

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6V1X1

UPID:

DPP8_HUMAN

Alternative names:

Dipeptidyl peptidase IV-related protein 1; Dipeptidyl peptidase VIII; Prolyl dipeptidase DPP8

Alternative UPACC:

Q6V1X1; Q7Z4C8; Q7Z4D3; Q7Z4E1; Q8IWG7; Q8NEM5; Q96JX1; Q9HBM2; Q9HBM3; Q9HBM4; Q9HBM5; Q9NXF4

Background:

Dipeptidyl peptidase 8 (DPP8), also known as Dipeptidyl peptidase IV-related protein 1 and Prolyl dipeptidase DPP8, plays a crucial role in protein metabolism. It specifically cleaves off N-terminal dipeptides from proteins with a Pro or Ala residue at position 2. DPP8 acts as a significant inhibitor of caspase-1-dependent pyroptosis in monocytes and macrophages by preventing the activation of NLRP1 and CARD8, thereby controlling inflammatory responses.

Therapeutic significance:

Understanding the role of Dipeptidyl peptidase 8 could open doors to potential therapeutic strategies, particularly in modulating immune responses and preventing inflammatory diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.